Drug Trial Radar · NCT03052725
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
391
Actual
Start
Mar 10, 2017
Primary completion
Feb 22, 2018
Study completion Feb 22, 2018
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.
Conditions
- Eosinophils, Asthma
Interventions
reslizumabDrug
Reslizumab was provided in a pre-filled syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug.
Locations
134 sites in 13 countries. Site status is shown where the registry gives one.
Teva Investigational Site 14647
Birmingham, Alabama
Teva Investigational Site 14631
Bakersfield, California
Teva Investigational Site 14648
Huntington Beach, California
Teva Investigational Site 14637
Napa, California
Teva Investigational Site 14654
Stockton, California
Teva Investigational Site 14636
Walnut Creek, California
Teva Investigational Site 14626
Aventura, Florida
Teva Investigational Site 14634
Homestead, Florida
Teva Investigational Site 14650
Miami, Florida
Teva Investigational Site 14629
Miami, Florida
Teva Investigational Site 14619
Miami, Florida
Teva Investigational Site 14624
Orlando, Florida
Teva Investigational Site 14638
Tallahassee, Florida
Teva Investigational Site 14642
Buford, Georgia
Teva Investigational Site 14651
Chicago, Illinois
Teva Investigational Site 14645
Michigan City, Indiana
Teva Investigational Site 14620
Owensboro, Kentucky
Teva Investigational Site 14623
Lafayette, Louisiana
Teva Investigational Site 14627
North Dartmouth, Massachusetts
Teva Investigational Site 14644
Boys Town, Nebraska
Teva Investigational Site 14652
Ocean City, New Jersey
Teva Investigational Site 14632
Lake Success, New York
Teva Investigational Site 14646
New York, New York
Teva Investigational Site 14633
Cincinnati, Ohio
Teva Investigational Site 14653
Cleveland, Ohio
Teva Investigational Site 14621
Edmond, Oklahoma
Teva Investigational Site 14625
Edmond, Oklahoma
Teva Investigational Site 14643
Jenkintown, Pennsylvania
Teva Investigational Site 14622
Pittsburgh, Pennsylvania
Teva Investigational Site 14630
East Providence, Rhode Island
Teva Investigational Site 14649
Providence, Rhode Island
Teva Investigational Site 14655
Knoxville, Tennessee
Teva Investigational Site 14639
Corsicana, Texas
Teva Investigational Site 14640
Dallas, Texas
Teva Investigational Site 14641
Provo, Utah
Teva Investigational Site 14628
Abingdon, Virginia
Teva Investigational Site 14635
Falls Church, Virginia
Teva Investigational Site 37082
Brussels, Belgium
Teva Investigational Site 37081
Erpent, Belgium
Teva Investigational Site 37083
Ghent, Belgium
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.